Ocular Therapeutix, Inc.(OCUL)Earnings, Financials & Key RatiosOcular Therapeutix, Inc. (OCUL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external capital is underscored by a persistent net loss of $88.6M in 2026Q1 and a lack of clear operating leverage to support its current $41.58 price-to-sales valuation.
Ocular Therapeutix, Inc. (OCUL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ocular Therapeutix, Inc. (OCUL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.41vs $0.32-28.1% | $11Mvs $13M-15.2% |
| Q1 2026 | Feb 5, 2026 | $0.29vs $0.33+12.1% | $13Mvs $16M-17.8% |
| Q4 2025 | Nov 4, 2025 | $0.37vs $0.39+5.1% | $15Mvs $16M-9.9% |
| Q3 2025 | Aug 5, 2025 | $0.39vs $0.35-11.4% | $13Mvs $15M-7.6% |
Recent stock market news and headlines for Ocular Therapeutix, Inc. (OCUL)
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.
BEDFORD, Mass. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. Upcoming Scientific Conferences: 9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026Montréal, Quebec Presentation: Ocular Therapeutix: Retina Experience RedefinedPresentation Date/Time: Tuesday, July 14, 2026, 11:37 - 11:44 AM EDTPresenter: Peter K.
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company's new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for AXPAXLI.
Key metrics vs top competitors for Ocular Therapeutix, Inc. (OCUL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.33 | $2.26B | -7.27 | -18.67% | -513.17% | -54.85% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $1.51 | $33.11M | -0.46 | — | — | -1335.64% | — | |
| $2.23 | $134.52M | -3.98 | — | — | -0% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $5.35 | $291.09M | -7.23 | -3.13% | -46.83% | -59.1% | — |
Ocular Therapeutix, Inc. (OCUL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ocular Therapeutix, Inc. (OCUL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Feb 27, 2026·SEC
Feb 5, 2026·SEC
Get notified when OCUL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ocular Therapeutix, Inc. (OCUL) stock FAQ — growth, dividends, profitability & financials explained
Ocular Therapeutix, Inc. (OCUL) reported $52.0M in revenue for fiscal year 2025. This represents a 520280% increase from $0.0M in 2012.
Ocular Therapeutix, Inc. (OCUL) saw revenue decline by 18.7% over the past year.
Ocular Therapeutix, Inc. (OCUL) reported a net loss of $290.5M for fiscal year 2025.
Ocular Therapeutix, Inc. (OCUL) has a return on equity (ROE) of -54.9%. Negative ROE indicates the company is unprofitable.
Ocular Therapeutix, Inc. (OCUL) had negative free cash flow of $240.9M in fiscal year 2025, likely due to heavy capital investments.
